Accéder au contenu
MilliporeSigma

860506P

Avanti

C6 Ceramide (d18:1/6:0)

Avanti Research - A Croda Brand

Synonyme(s) :

N-hexanoyl-D-erythro-sphingosine

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :
C24H47NO3
Numéro CAS:
Poids moléculaire :
397.63
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


assay

>99% (TLC)

form

powder

packaging

pkg of 1 × 10 mg (860506P-10mg), pkg of 1 × 5 mg (860506P-5mg)

manufacturer/tradename

Avanti Research - A Croda Brand

lipid type

sphingolipids

shipped in

dry ice

storage temp.

−20°C

SMILES string

OC[C@]([H])(NC(CCCCC)=O)[C@]([H])(O)/C=C/CCCCCCCCCCCCC

InChI

1S/C24H47NO3/c1-3-5-7-8-9-10-11-12-13-14-15-16-18-19-23(27)22(21-26)25-24(28)20-17-6-4-2/h18-19,22-23,26-27H,3-17,20-21H2,1-2H3,(H,25,28)/b19-18+

InChI key

NPRJSFWNFTXXQC-VHEBQXMUSA-N

General description

C6 Ceramide (d18:1/6:0) is a short chain and a cell permeable ceramide. It comprises amino alcoholic chain attached to fatty acyl chain via an amide linkage.

Application

C6 Ceramide (d18:1/6:0) has been used as a chemotherapeutic agent to test its anti-tumor effect in breast cancer cells and ovarian cancer cell lines. It has also been used to test chemo-sensitization effects in cancer cells.

Biochem/physiol Actions

C6 Ceramide (d18:1/6:0) is involved in inhibiting proliferation and inducing apoptosis. When used in combination with acid ceramidase inhibitor DM102, [(2R,3Z)-N-(1-hydroxyoctadec-3-en-2-yl)pivaloylamide], it favors cell death in human breast cancer cells lines. C6 Ceramide may serve as an adjunct in chemotherapy. It elicits anti-tumor effects via AKT (serine/threonine-specific protein kinase) dephosphorylation and α-tubulin acetylation.

Packaging

5 mL Amber Glass Screw Cap Vial (860506P-10mg)
5 mL Amber Glass Screw Cap Vial (860506P-5mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC


Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents



C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth
Flowers M, et al.
Breast Cancer Research and Treatment, 133(2), 447-458 (2012)
Q-y Zhu et al.
Cell death & disease, 2, e117-e117 (2011-03-04)
Histone deacetylase inhibitors (HDACIs) have shown promising anti-tumor effects for a variety of malignancies, however, many tumors are reportedly resistant to them. In this study, we made a novel discovery that co-administration of HDACIs (Trichostatin A (TSA) and others) and
C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study
Yang L, et al.
Experimental Cell Research, 332(1), 47-59 (2015)



Numéro d'article de commerce international

RéférenceGTIN
860506P-5MG04061835317479
860506P-10MG04061835317462